24/7 Market News Snapshot 20 May, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)

May 20, 2025

DENVER, Colo., 20 May, 2025 (www.247marketnews.com) – (NASDAQ:CING) are discussed in this article.
Cingulate Inc. (NASDAQ:CING) is currently facing a bearish market trend, highlighted by pre-market trading at $3.772, reflecting a decrease of approximately 0.997% from the previous day’s close of $3.810. The trading volume has reached 1.34 million shares, indicating notable market activity as investors react to recent developments. The stock is experiencing resistance at $3.81, while potential support lies around $3.70. As the market conditions remain volatile, investors are advised to exercise caution and carefully evaluate key indicators, including moving averages and trading volume, to identify possible reversal points.

Amidst this market activity, Cingulate has reported promising results from its pivotal Phase 3 clinical trial assessing the efficacy of CTx-1301 in treating Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric patients aged 6-17. The data demonstrates statistically significant reductions in ADHD symptoms across all fixed dosages of CTx-1301 in just five weeks, with robust effect sizes ranging from 0.737 to 1.185.

Dr. Raul R. Silva, Chief Science Officer, emphasized the importance of these results, noting CTx-1301’s potential as a first-line treatment for the millions affected by ADHD, particularly addressing significant unmet medical needs. Shane J. Schaffer, Chairman and CEO, shared enthusiasm for the outcomes, marking them as a crucial milestone for the company.

CTx-1301 utilizes Cingulate’s innovative Precision Timed Release™ platform and is poised for potential market introduction with a diverse range of eight dosage strengths, specifically designed for the pediatric population. The positive safety profile confirmed across multiple trials adds further strength to the drug’s viability, as Cingulate plans its New Drug Application submission to the FDA this summer. As the company continues to explore expansions in other therapeutic areas, it aims to transform ADHD management and enhance patient care through its breakthrough drug delivery technology.

Related news for (CING)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.